Literature DB >> 466931

Salicylate clearance, the resultant of protein binding and metabolism.

D E Furst, T N Tozer, K L Melmon.   

Abstract

Steady-state plasma salicylate concentrations and protein binding were examined in 9 normal subjects to determine relationships among daily dose, total and unbound salicylate concentrations, and total and unbound clearances. Aspirin doses ranging from 0.66 to 4.0 mg/kg/hr were given to steady state. Free and total salicylate concentrations were measured with spectrophotometric, fluorimetric, and equilibrium dialysis techniques. Although unbound clearance decreased over the therapeutic range, total clearance was unchanged. The former is a consequence of saturable metabolism; the latter, of saturable plasma protein binding as well as saturable metabolism. The fraction unbound increased linearly with unbound concentration. Clearance determined at 1.8 mg/kg/hr was used to predict levels obtained at higher aspirin doses. Analysis of residuals was used to ascertain the accuracy of the prediction. The coefficient of variation from prediction among subjects was found to be +/- 14%. It is concluded that, in normal subjects, salicylate clearance changes relatively little over the therapeutic range because the increasing fraction unbound compensates for decreasing clearance of unbound drug.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 466931     DOI: 10.1002/cpt1979263380

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  23 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

2.  Dose-dependent pharmacokinetics of MK-417, a potent carbonic anhydrase inhibitor, in experimental polycythemic and anemic rats.

Authors:  J H Lin; I W Chen; F A deLuna
Journal:  Pharm Res       Date:  1991-05       Impact factor: 4.200

Review 3.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

4.  The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man.

Authors:  R K Verbeeck; G R Loewen; J I MacDonald; R J Herman
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

5.  Generalized pharmacokinetic modeling for drugs with nonlinear binding: I. Theoretical framework.

Authors:  W R Gillespie
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

6.  Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease.

Authors:  M S Roberts; R H Rumble; S Wanwimolruk; D Thomas; P M Brooks
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Salicylate protein binding in serum from young and elderly subjects as measured by diafiltration.

Authors:  L J Lesko; P K Narang; L Yeager; N R Cutler
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose.

Authors:  J Shen; S Wanwimolruk; R D Purves; E G McQueen; M S Roberts
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

Review 9.  The problems and pitfalls of NSAID therapy in the elderly (Part II).

Authors:  A G Johnson; R O Day
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 10.  Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.

Authors:  J H Lin; D M Cocchetto; D E Duggan
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.